



### References on the Administration of Neurotensin Using ALZET® Osmotic Pumps

**Q0038:** J. H. Cooke, *et al.* Peripheral and Central Administration of Xenin and Neurotensin Suppress Food Intake in Rodents. *Obesity* 2009;17(6):1135-1143

**ALZET Comments:** Xenin; neurotensin; SC; Mice; 1007D; 6 days; Controls received mp w/ saline; peptides; no stress (pg 1142); animal info (male, C57BL/6); comparison of IP injections vs. SC mp; dose-response (table 1); functionality of mp verified by residual volume.

**P9874:** C. Norman, *et al.* Effects of chronic infusion of neurotensin and a neurotensin NT<sub>1</sub> selective analogue PD149163 on amphetamine-induced hyperlocomotion. *JOURNAL OF PSYCHOPHARMACOLOGY* 2008;22(3):300-307

**ALZET Comments:** Neurotensin; PD149163; Saline; CSF/CNS; Rat; 7, 21 days; Controls received mp w/ vehicle; ALZET brain infusion kit 2 used; animal info (lister hooded, 250-300 g.); cannula placement verified by histological assessment; PD149163 is an NT<sub>1</sub> selective analogue.

**P8672:** E. Popp, *et al.* Time course of the hypothermic response to continuously administered neurotensin. *Neuropeptides* 2007;41(5):349-354

**ALZET Comments:** Neurotensin; Saline; CSF/CNS; Rat; 1003D; Controls received mp w/ vehicle; dose-response (pg 351, fig. 1); comparison of SC injections vs. mp; ALZET brain infusion kit 2 used; tolerance; peptides; animal info (Wistar-Han, male, 300-350g); "Diffusion of neurotensin into the pump was avoided by a drop of sesame oil" p. 350; "Complete surgery took about 20 min" p. 350; neurotensin is a tridecapeptide.

**P7131:** P. Brun, *et al.* Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. *American Journal of Physiology-Gastrointestinal and Liver Physiology* 2005;288(4):G621-G629

**ALZET Comments:** Neurotensin; PBS; BSA; SC; Mice; 2002; 5 days; Controls received mp w/ vehicle; peptides; wound healing.

**P5015:** A. Kramer, *et al.* Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. *Science* 2001;294(5551):2511-2515

**ALZET Comments:** Transforming growth factor- $\alpha$ ; Brain-derived neurotrophic factor; Vasoactive intestinal polypeptide; Peptide, histidine-isoleucine; Gastrin releasing peptide; Substance P; Neuromedin-C; Neurokinin A; Neuropeptide K; Neuropeptide Y; Somatostatin; Antrin; Cholecystokinin; Thyrotropin-releasing hormone; Neurotensin; Neuromedin N;; CSF, artificial; CSF/CNS (third ventricle); hamster; 2002; 18-22 days; peptides.

**P4409:** J.-J. Maoret, *et al.* Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. *Int. J. Cancer* 1999;80(4):448-454

**ALZET Comments:** Neurotensin; PBS; BSA; SC; Mice (nude); 22 days; Controls received mp w/vehicle; cancer; peptides.

**P6307:** C. K. Rayn, *et al.* Epidermal Growth Factor and Neurotensin Induce Microvillus Hypertrophy Following Massive Enterectomy. *JOURNAL OF GASTROINTESTINAL SURGERY* 1996;1(5):467-473

**ALZET Comments:** Epidermal growth factor; neurotensin; Saline; SC; Rabbit; 1 week; Controls received mp w/ vehicle; replacement therapy (enterectomy); good methods p.468; peptides; post op. care (IM gentamycin; IV banamine).

**P3251:** A. D. Campbell, *et al.* Changes in mouse brain neurotensin receptor density following chronic infusion of neurotensin. *Peptides* 1995;16(3):501-504

**ALZET Comments:** Neurotensin; Saline; CSF/CNS; mice; 3, 7 days; controls received mp w/saline; peptides; loop of tubing allowed flow cessation.

**P2713:** I. Dubuc, *et al.* Tolerance to the hypothermic but not to the analgesic effect of (D-Trp<sup>11</sup>)neurotensin during the semichronic intracerebroventricular infusion of the peptide in rats. *Peptides* 1994;15(2):303-307



**ALZET Comments:** Neurotensin, (D-Trp11)-; Saline; CSF/CNS; Rat; 2002; 10 days; controls received mp w/ saline; comparison of icv injections vs. mp; peptides; tolerance; (D-Trp11)neurotensin is a peptidase-resistant derivative of neurotensin, allowing a longer duration of effect without inactivation.

**P3267:** L. K. Malendowicz, *et al.* Effects of prolonged administration of neurotensin, arginine-vasopressin, NPY, and bombesin on blood TSH, T3, and T4 levels in the rat. *In Vivo* 1990;4(259-262

**ALZET Comments:** Neurotensin; Vasopressin, arginine; Bombesin; Saline; IP; Rat; 7,8 days; controls received mp w/saline; peptides.

**R0089:** A. Amkraut, *et al.* Osmotic delivery of peptides and macromolecules. *Adv. Drug Delivery Review* 1990;4(255-276

**ALZET Comments:** Atrial natriuretic factor; cholecystokinin; Granulocyte-colony stimulating factor.; glucagon; insulin; interleukin-2; interleukin-3; melatonin; nerve growth factor; neurotensin; prolactin; theophylline; CSF/CNS; IA (femoral); intrasplenic; IP; SC; no duration posted; peptides; ALZA-authored, review of peptide delivery issues and applications; tissue perfusion (spleen).

**P0783:** G. E. Feurle, *et al.* Action of neurotensin on size, composition, and growth of pancreas and stomach in the rat. *Regul. Pept* 1985;13(1):53-62

**ALZET Comments:** Neurotensin; SC; Rat; 2002; 14 days; controls received mp size plastic cylinders; injection vs. infusion; 2 doses of agent infused; functionality of mp verified (pump rates);stress/adverse reaction (local infection at site of implantation); peptides.

**P0572:** S. M. Simasko, *et al.* Effect of neurotensin, substance P and TRH on the regulation of dopamine receptors in rat brain. *Eur. J. Pharmacol* 1984;106(3):653-656

**ALZET Comments:** Neurotensin; Substance P; Thyrotropin-rel. factor; Saline; CSF/CNS; Rat; 8 days; portion of tubing connecting mp to icv cannula was externalized to allow shut off of flow; stability of agents verified; concomitant haloperidol admin.; peptides.

**P0512:** L. Peric-Golia, *et al.* The effect of neurotensin on the concentration of cholesterol and bile acids in the guinea pig. *Lipids* 1984;19(10):749-755

**ALZET Comments:** Neurotensin; Saline; SC; Guinea pig; 3-5 days; comparison of single iv injec vs. mp infusion; release rate performance of mp verified; peptides.

**P0332:** A. Cowan, *et al.* Defining the antinocisponsive actions of neurotensin. *Ann. N. Y. Acad. Sci* 1982;400(438-439

**ALZET Comments:** Morphine; Neurotensin; Saline; CSF/CNS; SC; Rat; 2001; 1 week; peptides.